12/23
08:00 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $32.00 price target on the stock.
Medium
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $32.00 price target on the stock.
12/10
11:08 am
cmpx
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Neutral
Report
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
12/10
08:14 am
cmpx
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer [Yahoo! Finance]
Medium
Report
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer [Yahoo! Finance]
12/10
08:00 am
cmpx
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
Medium
Report
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
12/2
08:00 am
cmpx
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Low
Report
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
11/16
06:03 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Low
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
11/15
09:09 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $4.00 price target on the stock, down previously from $5.00.
High
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $4.00 price target on the stock, down previously from $5.00.
11/13
08:30 am
cmpx
Compass Therapeutics to Participate in Upcoming Investor Events
High
Report
Compass Therapeutics to Participate in Upcoming Investor Events
11/12
08:00 am
cmpx
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
Medium
Report
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
11/11
08:09 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/8
10:10 am
cmpx
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]
Low
Report
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]
11/8
10:05 am
cmpx
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Low
Report
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/4
10:31 am
cmpx
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
Low
Report
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting